September 24, 2020
NIH has awarded approximately $10 million to support implementation science research to advance the goals of Ending the HIV Epidemic: A Plan for America, which aims to reduce new HIV diagnoses in the United States by at least 90% by 2030. Some of the awards continue and expand on pilot projects funded in 2019, while others support new projects.
August 14, 2020
With 7,770 participants enrolled in 12 countries across five continents, the REPRIEVE study is evaluating the ability of a statin medication to reduce the risk of heart disease among people with HIV. By leveraging data collected from this diverse group of study participants, researchers also are learning more about the long-term health effects of HIV.
July 20, 2020
NIAID and IAVI, a nonprofit scientific research organization, recently announced a collaboration to develop combinations of HIV broadly neutralizing antibodies that could be produced on a large scale at low cost to prevent and possibly treat HIV. This initiative also will leverage IAVI’s existing partnership with the Serum Institute of India Pvt. Ltd. to develop an affordable and globally accessible antibody-based HIV prevention product.
July 10, 2020
In his final interview with HIV.gov at AIDS 2020: Virtual, NIAID's Dr. Carl Dieffenbach discussed HIV vaccine development, a new partnership to expedite development of HIV antibody combination products, NIH’s engagement in the Ending the HIV Epidemic initiative, and a look to what’s on the horizon in HIV research in the year ahead.
July 09, 2020
Presentations and discussions about the latest HIV research continued at AIDS 2020: Virtual yesterday. HIV.gov shared an interview with Carl Dieffenbach, Ph.D., director of NIAID's Division of AIDS. He discussed additional data from the Tsepamo study on the prevalence of neural tube defects among infants born to women taking the HIV drug dolutegravir at the time of conception, 96-week findings from the South African ADVANCE trial comparing three first-line HIV treatment regimens, and evidence of weight gain caused by different HIV drugs.
July 08, 2020
The 23rd International AIDS Conference (AIDS 2020: Virtual) moved online this year. After the first full day of sessions at which HIV researchers from around the globe shared new scientific findings, HIV.gov spoke about some of the highlights with Carl Dieffenbach, Ph.D., director of the Division of AIDS at NIAID.
June 02, 2020
NIAID researchers found that short-term interruption of HIV treatment with modern antiretroviral therapy (ART) regimens results in similar outcomes compared to historical “analytical treatment interruption” data from participants treated with older ART regimens. Their findings will support future HIV cure studies by updating the control group data to which experimental outcomes are compared.
May 17, 2020
Decades of scientific advances have led to development and implementation of highly effective HIV treatment and prevention tools, strengthening optimism for achieving a durable end to the HIV pandemic. Yet a safe and effective HIV vaccine remains elusive. On HIV Vaccine Awareness Day 2020, NIAID honors the researchers and clinical study participants who play essential roles in advancing HIV vaccine development.
March 06, 2020
The cancer drug paclitaxel and a suppressive regimen of antiretroviral therapy is an effective treatment for AIDS-related Kaposi’s sarcoma, according to researchers who conducted a clinical trial comparing three chemotherapy regimens in combination with antiretroviral therapyin people with advanced AIDS-Kaposi’s sarcoma in Africa and South America.
January 16, 2020
The first clinical trial to test the combination of a long-acting anti-HIV drug plus a powerful HIV antibody as a long-acting treatment for people living with HIV has begun. Investigators are studying whether long-acting cabotegravir and an antibody called VRC07-523LS are safe and tolerable and prevent HIV from rebounding to detectable levels in people who previously kept the virus suppressed with daily antiretroviral therapy.
December 23, 2019
NIAID Now looks back at highlights of 2019.
November 15, 2019
Antiretroviral therapy (ART) is used to treat HIV infection by suppressing levels of virus in the body. Researchers have found that reducing levels of virus through ART prevents transmission of virus from person to person. However, interruption of ART can allow levels of HIV to increase, resulting in HIV transmission or progression of disease. Many clinical trials evaluating possible HIV cure strategies include interruption of ART to determine the length of time the virus remains suppressed and establish the short-term safety of such interruptions.
People with HIV Can Give the Gift of Life by Becoming Organ Donors – A Q&A with HIV Transplantation Experts
November 13, 2019
Organ donation saves lives. Unfortunately, 20 people die each day waiting for a transplant—including people living with HIV, who are more likely than HIV-negative people to develop end-stage kidney and liver disease. The HOPE Act of 2013 allows for research into organ transplantation from one person with HIV to another. To learn more about how researchers are leveraging this legislation, NIAID Now spoke to two HIV transplantation experts.
November 04, 2019
Since the HIV epidemic emerged in the 1980s, extraordinary progress has been made in understanding, treating, and preventing HIV. Yet HIV stigma persists. NIAID Now spoke with Dianne Rausch, Ph.D., and Gregory Greenwood, Ph.D., of NIH’s National Institute of Mental Health about stigma, its effects on health, and how research is informing strategies to reduce stigma and improve HIV outcomes.
October 03, 2019
Tuberculosis (TB) is the leading cause of death for people with HIV. Among women, TB predominantly affects people of childbearing age. When active TB disease develops during pregnancy or in the weeks after birth, it is associated with poor health outcomes for both the mother and baby.
August 15, 2019
HIV damages the immune system by targeting and killing infection-fighting white blood cells known as CD4+ T cells, or CD4 cells. Usually, the number of CD4 cells in a person’s blood recovers when HIV is controlled with effective antiviral treatment. However, even when combination antiretroviral therapy (ART) controls the virus, 15% to 30% of people with HIV have very slow or minimal recovery in CD4 cell counts.
HIV Treatment Advances and Other Final HIV Research Updates from the 2019 IAS Conference on HIV Science
July 25, 2019
Advances in HIV treatment options and studies on HIV prevention for women and girls were among the highlights yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019). On the third and final day of the conference, NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss those studies, reflect on key meeting takeaways, and look ahead to research developments on the horizon.
July 24, 2019
HIV prevention research was in the spotlight yesterday at the second full day of presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019). NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss research about an experimental implantable form of PrEP and other findings that inform HIV prevention and treatment interventions.
HIV Research Updates from NIH’s Dr. Carl Dieffenbach at the 10th IAS Conference on HIV Science (IAS 2019)
July 23, 2019
As the 10th International AIDS Society Conference on HIV Science, or IAS 2019, opened in Mexico City, HIV.gov hosted a Facebook Live session with NIAID's Carl Dieffenbach, Ph.D., about initial research presented there and what is in store. Dr. Dieffenbach spoke with his colleague Anne Rancourt. They previewed a topic to be discussed at the conference: what’s new in the HIV prevention landscape, including HIV vaccine research. They also discussed new findings presented on Monday about a potential association between the HIV treatment medication dolutegravir and birth defects.
July 23, 2019
How to end the HIV epidemic is a theme of many conversations and presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. After delivering presentations on that topic, NIAID Director Dr. Anthony Fauci shared his thoughts with HIV.gov. He observed that we now have the HIV prevention and treatment tools that, if implemented properly and aggressively, could theoretically end the HIV epidemic. He also acknowledged that implementation is a key issue and that there is a need for continued innovation and research.
June 26, 2019
When countries began providing HIV treatment to all people diagnosed with the virus, regardless of their immune health, the proportion of people who started treatment within a month of enrolling in HIV care jumped sharply in some nations, a study has found.
June 05, 2019
As NHLBI, NIAID, the Office of AIDS Research, and other NIH components adapt to the changing epidemiology of HIV infection, we are working together to support a coordinated research agenda that will optimize the health of people with HIV and improve their quality of life by reducing HIV-related co-morbidities. This year, on HIV Long-Term Survivors Day, we renew our commitment to study HIV disease across the lifespan.
May 29, 2019
Researchers launched the Randomized Trial to Prevent Vascular Events in HIV, or REPRIEVE, in 2015 with support from NIAID and the National Heart, Lung and Blood Institute. The ambitious trial is testing the ability of a statin medication to reduce the risk of heart disease in men and women with HIV. Researchers completed the enrollment phase of the trial earlier this year, welcoming more than 7,500 participants in eleven countries. REPRIEVE investigators and NIAID collaborators discussed the design and goals of the trial in the June issue of the American Heart Journal.
May 22, 2019
At the National Institute of Allergy and Infectious Diseases, we are proud of our legacy in HIV research, and we look for every opportunity to strengthen the ways we and our partners conduct clinical research and ensure that the trials we sponsor meet our regulatory responsibilities. Last year, the NIAID Division of AIDS initiated a mock inspection to evaluate the processes and systems associated with our clinical trial operations.
May 13, 2019
The National Institute of General Medical Sciences (NIGMS) has a rich history of fostering fundamental HIV research. Recently, NIGMS leadership had the strategic insight that this portfolio should be combined with the existing basic research program at NIAID to maximize collaboration and better leverage existing resources. NIGMS has excelled in fostering this research for 37 years, and we are honored to welcome their researchers into our scientific community.